Adult Dosing

Immunization against influenza virus

• 0.5 mL IM x1 annually

Pediatric Dosing

Immunization against influenza virus (Fluzone Quadrivalent)

• Children 6-35 month
• 0.25 mL IM, may followed by a second 0.25 mL dose after 4 weeks for those who are receiving the influenza vaccine for the first time or were vaccinated for the first time last season with only 1 dose

• Children 36 months-8 yrs
• 0.5 mL IM, may followed by a second 0.5 mL dose after 4 weeks for those who are receiving the influenza vaccine for the first time or were vaccinated for the first time last season with only 1 dose

• Children >9 yrs
• 0.5 mL IM x 1 annually

Immunization against influenza virus (Fluarix Quadrivalent, FluLaval Quadrivalent)

• Children 3-8 years
• 0.5 mL IM, may followed by a second 0.5 mL dose after 4 weeks for those who are receiving the influenza vaccine for the first time or were vaccinated for the first time last season with only 1 dose

• Children >9 yrs
• 0.5 mL IM x 1 annually

• Active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine

• Hypersensitivity to any of the ingredients of the product
• Severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after previous dose of any influenza vaccine

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Persons known to have experienced Guillain-Barré syndrome within 6 wk after a previous influenza vaccination should not receive influenza virus vaccine, unless the benefit outweighs the risk
• Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions which may occur following administration
• Immunocompromised persons, including those receiving immunosuppressive therapy may have a reduced antibody response to inactivated influenza vaccine and may remain susceptible despite immunization
• Fever and febrile seizures have been reported in children predominantly below the age of 5 years, do not administer unless the benefit outweighs the risk
• Influenza vaccination may not protect all persons
• Syncope reported with injectable vaccines including Fluarix Quadrivalent
• Tip of syringe may contain natural rubber latex which may cause allergic reactions in latex-sensitive individuals

Pregnancy Category:C

Breastfeeding: The Centers for Disease Control and Prevention states that vaccines given to a nursing mother does not affect breastfed infants and breastfeeding is not a contraindication to influenza vaccine. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 17 June 2013). Manufacturer advises caution.

• CNS: Fever, drowsiness, malaise, headache, irritability
• RESP: Cough, URTI, viral infection, LRTI, wheezing, ear ache
• LOCAL: Pain, tenderness, swelling, erythema, tenderness
• MUSC: Myalgia
• GI: Appetite loss, vomiting
• HEMA: Ecchymosis

• Vaccine; forms specific antibodies that protect against influenza A (H1N1 and H3N2) and influenza B viruses or closely related strains
• Metabolism: Other
• Excretion: Other
• Half-life: Unknown

US Trade Name(s)

• Fluzone Quadrivalent
• Fluarix Quadrivalent
• FluLaval Quadrivalent

US Availability

Fluzone Quadrivalent

• INJ: 0.25 mL single dose prefilled syringes
• INJ: 0.5 mL single dose prefilled syringes

Fluarix Quadrivalent

• INJ: 0.5 mL single dose prefilled syringes

FluLaval Quadrivalent

• Inj: 5 mL multi dose vial(0.5 mL x 10 doses)

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Immunologic

Vaccines

Viral